Ebola hope? favipiravir trial shows mixed results
NCT ID NCT02329054
First seen Nov 18, 2025 · Last updated Jun 21, 2026 · Updated 31 times
Summary
This study tested the antiviral drug favipiravir in 126 people with Ebola in Guinea. Participants received high doses of the drug for 10 days. The goal was to see if it could lower the death rate. Results suggested a possible benefit for patients with low to moderate virus levels, but not for those with high virus levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ALIMA Ebola care center
Nzérékoré, Guinea
-
French Red Cross Ebola care center
Macenta, Guinea
-
MSF Ebola treatment centre
Gueckedou, Guinea
-
The caregivers treatment center
Conakry, Guinea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
favipiravir (an antiviral drug)
What this could lead to
If successful, this could provide a treatment option to reduce deaths from Ebola virus disease.
What could go wrong
This was a small, early-phase trial without a placebo group, so results are uncertain. The drug may not work for patients with high virus levels.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.